UPCOMING WEBINAR: New Peptide-based PET Ligands

Date: November 19, 2018

Time: 3:00pm EST

Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers

Ken Herrmann, MD, MBA
Universitatsklinikum Essen

Ken Herrmann, MD, received his medical degree in 2004 from Charité Berlin (Germany), after studying also at Université de Lausanne (Switzerland), Universidad Austral (Chile) and Memorial-Sloan Kettering Cancer Center (USA). He completed residency training in nuclear medicine at the Technische Universität München. Meanwhile, he completed a fellowship at Hokkaido University (Japan) and received an executive MBA degree from the University of Zürich (Switzerland). Since 2011, Dr. Herrmann has held a faculty position at the Department of Molecular and Medical Pharmacology at the University of California Los Angeles. He is also Chair of the Department of Nuclear Medicine, Universitatsklinikum Essen, and a member of the board of directors at SOFIE. He focuses on close collaborations with clinical partners in the fields of oncology and theranostics.

In this session, Dr. Herrmann will:

• Outline current research efforts in PET imaging and associated therapies focused on selected peptide-based tracers that target a variety of disease-related receptors and biomarkers

• Review new ligands which are exhibiting promising characteristics in binding affinity, uptake, retention, clearance from non-target tissue, stability and integrity in vivo, as well as relative ease in preparation

• Discuss the challenges and potential in the development of these compounds for targeted molecular imaging and delivery of therapeutic treatment

Register now to receive weblink: https://attendee.gotowebinar.com/register/659812921311267585

Seth Werkheiser